The price-to-earnings ratio for Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is above average at 30.49x. The 36-month beta value for VRTX is also noteworthy at 0.39. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 10 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for VRTX is 257.37M, and at present, short sellers hold a 1.74% of that float. The average trading volume of VRTX on July 04, 2024 was 1.17M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) has experienced a decline in its stock price by -0.80 compared to its previous closing price of 473.78. However, the company has seen a fall of -0.84% in its stock price over the last five trading days. investorplace.com reported 2024-07-03 that Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.
VRTX’s Market Performance
Vertex Pharmaceuticals, Inc. (VRTX) has seen a -0.84% fall in stock performance for the week, with a -0.04% decline in the past month and a 14.97% surge in the past quarter. The volatility ratio for the week is 2.07%, and the volatility levels for the past 30 days are at 1.86% for VRTX. The simple moving average for the past 20 days is -1.23% for VRTX’s stock, with a 15.74% simple moving average for the past 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Redburn Atlantic repeating the rating for VRTX by listing it as a “Buy.” The predicted price for VRTX in the upcoming period, according to Redburn Atlantic is $545 based on the research report published on June 27, 2024 of the current year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $438. The rating they have provided for VRTX stocks is “Outperform” according to the report published on April 11th, 2024.
Wolfe Research gave a rating of “Outperform” to VRTX, setting the target price at $515 in the report published on February 15th of the current year.
VRTX Trading at 5.55% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.38% of loss for the given period.
Volatility was left at 1.86%, however, over the last 30 days, the volatility rate increased by 2.07%, as shares sank -0.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.59% upper at present.
During the last 5 trading sessions, VRTX fell by -0.78%, which changed the moving average for the period of 200-days by +34.79% in comparison to the 20-day moving average, which settled at $475.62. In addition, Vertex Pharmaceuticals, Inc. saw 15.51% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Bozic Carmen, who sale 2,280 shares at the price of $471.72 back on Jun 26 ’24. After this action, Bozic Carmen now owns 30,099 shares of Vertex Pharmaceuticals, Inc., valued at $1,075,522 using the latest closing price.
Atkinson Edward Morrow III, the EVP, Chief Technical Ops. Off. of Vertex Pharmaceuticals, Inc., sale 7,288 shares at $478.00 during a trade that took place back on Jun 12 ’24, which means that Atkinson Edward Morrow III is holding 15,972 shares at $3,483,664 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- 0.41 for the present operating margin
- 0.87 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc. stands at 0.39. The total capital return value is set at 0.21. Equity return is now at value 24.38, with 18.74 for asset returns.
Based on Vertex Pharmaceuticals, Inc. (VRTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 5.47. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 96.5.
Currently, EBITDA for the company is 3.93 billion with net debt to EBITDA at -1.78. When we switch over and look at the enterprise to sales, we see a ratio of 11.09. The receivables turnover for the company is 5.68for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.
Conclusion
In summary, Vertex Pharmaceuticals, Inc. (VRTX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
